Thu. 20 Jun 2024, 8:53am ET
Benzinga
Biotech, News, General
- 21 months median OS in amezalpat arm vs. 15 in control arm
- 50% (20/40) of patients on amezalpat arm remain in survival follow up
- 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier
- Early and persistent separation of survival curves
- OS is the primary regulatory endpoint for first-line HCC
- Company to host webcast conference call today at 8:30am ET